文章摘要

恩度联合EGFR-TKI治疗老年非小细胞肺癌的临床观察

作者: 1林秋菊, 2张敏, 1李文慧, 1程鑫, 3魏红梅
1 青岛市肿瘤医院内二科,山东 青岛 266042
2 青岛市肿瘤医院健康管理中心,山东 青岛 266042
3 青岛市肿瘤医院肿瘤综合二科,山东 青岛 266042
通讯: 魏红梅 Email: 13001776675@163.com
DOI: 10.3978/j.issn.2095-6959.2020.10.010

摘要

目的:评价恩度联合靶向治疗药物[表皮生长因子受体-酪氨酸激酶抑制剂(epidermal growth factor receptor-tyrosine kinase inhibitor,EGFR-TKI),易瑞沙或特罗凯]一线治疗晚期老年非小细胞肺癌(non-small cell lung cancer,NSCLC)的临床价值。方法:纳入符合入组条件的晚期NSCLC患者90例,均经过EGFR检测(19,L858突变),45例患者给予易瑞沙250 mg,1次/d或特罗凯150 mg,1次/d口服,同时给予恩度30 mg静脉滴注(d1~7),与45例单用EGFR-TKI的晚期老年NSCLC患者进行对比分析。结果:联合用药组45例患者可评价疗效,其疾病控制率(disease control rate,DCR)较对照组明显提高,差异有统计学意义(P<0.05)。联合用药组患者的生活质量改善,明显优于单用EGFR-TKI组,差异有统计学意义(P<0.05)。患者对皮疹及腹泻等不良反应可耐受。结论:患者一线应用恩度联合EGFR-TKI的DCR高,生活质量改善,且不良反应可耐受。
关键词: 非小细胞肺癌;靶向药物;抗血管生成药物;恩度

Clinical observation of Endostar combined with EGFR-TKI in the treatment of elderly non-small cell lung cancer

Authors: 1LIN Qiuju, 2ZHANG Min, 1LI Wenhui, 1CHENG Xin, 3WEI Hongmei
1 Second Department of Internal Medicine, Qingdao Cancer Hospital, Qingdao Shandong 266042, China
2 Health Management Centre, Qingdao Cancer Hospital, Qingdao Shandong 266042, China
3 Second Department of Comprehensive Oncology, Qingdao Cancer Hospital, Qingdao Shandong 266042, China

CorrespondingAuthor: WEI Hongmei Email: 13001776675@163.com

Abstract

Objective: To evaluate the clinical value of Endostar combined with targeted therapy [epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), Iressa, or Tarceva] in the treatment of advanced elderly non-small cell lung cancer (NSCLC). Methods: Ninety patients with advanced NSCLC who met the enrollment conditions were all tested for EGFR (19, L858 mutation). 45 patients were given oral Iressa 250 mg qd or Tarceva 150 mg, once a day orally, and 30 mg, once a day of Endostar were administered as intravenous drip (d1–7), a comparative analysis was performed with 45 elderly patients with advanced NSCLC who received EGFR-TKI alone as a control group. Results: Forty-five patients in the combined drug group evaluated the efficacy, and the disease control rate (DCR) rate was significantly higher than that in the control group, and the difference was statistically significant (P<0.05). The improvement in quality of life was significantly better than that in the control group, and the difference was statistically significant (P<0.05). In addition, patients were tolerable to adverse reactions such as rash and diarrhea. Conclusion: First-line application of Endostar combined with EGFR-TKI has high disease control rate, improved quality of life, and tolerable side effects.
Keywords: non-small cell lung cancer; targeted drugs; anti-angiogenic drugs; Endostar